Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation
- PMID: 21251068
- DOI: 10.1111/j.1440-1746.2011.06664.x
Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation
Abstract
Background and aim: Type 2 diabetes increases the risk of cancer development and mortality. However, antidiabetic treatment with metformin can reduce the risk of cancer. We studied whether metformin users among diabetic patients with early hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA) would have a favorable survival compared with those without metformin treatment.
Methods: A total of 135 patients with early stage HCC having 162 tumors underwent RFA. Among them, 53 patients were diabetic, including 21 metformin users and 32 patients without metformin treatment.
Results: Diabetic patients had an inferior survival rate compared with nondiabetic patients (1 year, 82.8% vs 93.9%; 3 years, 55.1% vs 80.2%; 5 years, 41.3% vs 64.7%; P = 0.004). With regards to antidiabetic treatments, metformin users had better survival outcome (adjusted hazard ratio [HR] 0.24; 95% confidence interval [CI], 0.07-0.80; P = 0.020) compared to patients without metformin treatment after adjustments for potential confounders. Sulfonylureas and insulin exposures did not achieve significant conclusions. For the whole studied population including nondiabetic and diabetic patients, the multivariate analysis revealed that maximum tumor size more than 2.5 cm (HR, 3.49; 95% CI, 1.74-6.99; P < 0.001) and diabetic patients without metformin treatment (HR, 3.34; 95% CI, 1.67-6.71, P = 0.001) were independent explanatory variables associated with unfavorable survival.
Conclusions: Metformin users among diabetic patients with HCC undergoing RFA had a favorable overall survival compared with patients without metformin treatment.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
Similar articles
-
Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model.Liver Int. 2011 May;31(5):692-9. doi: 10.1111/j.1478-3231.2011.02480.x. Epub 2011 Feb 21. Liver Int. 2011. PMID: 21457441
-
Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index.Eur J Gastroenterol Hepatol. 2011 Jun;23(6):528-36. doi: 10.1097/MEG.0b013e328346d529. Eur J Gastroenterol Hepatol. 2011. PMID: 21537128
-
Tolerance of radiofrequency ablation by patients of hepatocellular carcinoma.J Hepatobiliary Pancreat Surg. 2009;16(5):655-60. doi: 10.1007/s00534-009-0103-9. Epub 2009 Apr 17. J Hepatobiliary Pancreat Surg. 2009. PMID: 19370304
-
Recent advances of radiofrequency ablation for early hepatocellular carcinoma.J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:115-22. doi: 10.1111/j.1440-1746.2010.06543.x. J Gastroenterol Hepatol. 2011. PMID: 21199522 Review.
-
Radiofrequency ablation vs. surgical resection on the treatment of patients with small hepatocellular carcinoma: a system review and meta-analysis of five randomized controlled trials.Hepatogastroenterology. 2014 Sep;61(134):1722-9. Hepatogastroenterology. 2014. PMID: 25436369 Review.
Cited by
-
Metformin, an old drug, brings a new era to cancer therapy.Cancer J. 2015 Mar-Apr;21(2):70-4. doi: 10.1097/PPO.0000000000000103. Cancer J. 2015. PMID: 25815846 Free PMC article. Review.
-
Insulin resistance and metabolic hepatocarcinogenesis with parent-of-origin effects in A×B mice.Am J Pathol. 2011 Dec;179(6):2855-65. doi: 10.1016/j.ajpath.2011.08.014. Epub 2011 Oct 1. Am J Pathol. 2011. PMID: 21967816 Free PMC article.
-
Targeting the Metabolic Paradigms in Cancer and Diabetes.Biomedicines. 2024 Jan 17;12(1):211. doi: 10.3390/biomedicines12010211. Biomedicines. 2024. PMID: 38255314 Free PMC article. Review.
-
Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis.PLoS One. 2015 Jun 1;10(6):e0127967. doi: 10.1371/journal.pone.0127967. eCollection 2015. PLoS One. 2015. PMID: 26030161 Free PMC article. Review.
-
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.Indian J Endocrinol Metab. 2018 May-Jun;22(3):421-428. doi: 10.4103/ijem.IJEM_585_17. Indian J Endocrinol Metab. 2018. PMID: 30090738 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
